Etoricoxib and anastrozole in adjuvant early breast cancer: ETAN trial (phase III).

Rosati, Maria Sofia; Seri, M. Di; Baciarello, Giulia; Russo, V. Lo; Grassi, Paolo; Marchetti, Luca; Galimberti, Sara; Basile, Marco; Frati, Luigi

doi:10.1200/jco.2011.29.15_suppl.533

Search citation statements

Order By: Relevance

Paper Sections

Select...

Results2

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2017

2024

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 5 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients in all three RCTs experienced a reduction in pain, which was the primary outcome (36,43,44). In the trial by Birrell et al (43), which has only been published as an abstract, 80mg testosterone resulted in a 70% decrease in Visual Analogue Scores (VAS) scores at 3 months, compared to only 35% decrease in VAS scores in the placebo arm (p=0.04).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Management of aromatase inhibitor induced musculoskeletal symptoms in postmenopausal early Breast cancer: A systematic review and meta-analysis

Roberts

Rickett

Greer

et al. 2017

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

“…The use of testosterone was not associated with a significant elevation in serum oestradiol. Rosati et al studied the use of etoricoxib (60mg/day) versus placebo, in addition to anastrozole (44). This study has also only been published as an abstract.…”

Section: Resultsmentioning

confidence: 99%